Surrogate endpoints in AIDS drug development: Current status

Drug Information Journal

Volumn 32, Issue 2, 1998, Pages 439-448

  Chuang Stein, Christy ^a  

^a PFIZER INC   (United States)

Author keywords

Clinical endpoints; Surrogate Marker Collaborative Group; Validation of surrogate markers; Viral load reduction

Indexed keywords

ANTIGEN P24; ANTIRETROVIRUS AGENT; BETA 2 MICROGLOBULIN; CD4 ANTIGEN; LAMIVUDINE; NEOPTERIN; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; DISEASE COURSE; DRUG DEVELOPMENT; DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; VIRUS REPLICATION;

EID: 0031780268     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286159803200215     Document Type: Review

References (17)

1. Fleming TR. Surrogate endpoints in clinical trials. DruglnfJ. 1996;30:545-551.
2. Fleming TR, DeMets DL. Surrogate endpoints in clinical trials: Are we being misled? Ann Intern Med. 1996:125:605-613.
3. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engt J Med. 1991;324:781-788.
4. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators. N Engl 3 Med. 1992:327:227-233.
5. Packer M, Carver JR, Rodehoffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991:325:1468-1475.
6. Packer M, Rouleau J, Swedberg K, Pitt B, Fisher L, Klepper M, et al. Effect of Flosequinan on survival in chronic heart failure: preliminary results of the PROFILE study (Abstract). Circulation. 1993; 88(Suppl 1):1-301.
7. Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR. December 1992;41(suppl RR17):1-13.
8. 0'Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte count and the risk of progression to AIDS. N Eng J Med. 1996:334:426-431.
9. CAESAR Coordinating Committee. Randomised trial of the addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet. 1997;349:14I3-1421.
10. Hammer SM, Demeter LM, Fischl MA, et al. Clinical, immunological and virological outcomes in ACTG320, a randomised, placebo controlled trial of indinavir in combination with two nucleosides in HIV-1 infected persons with CD4+ cell counts 200/mmJ. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, June 28-30 1997, St. Petersburg, FL. Abstract #67.
11. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1 infected compartments during combination therapy. Comments in: Nature. May 1997:387(6629): 188-191.
12. Points to Consider in the Assessment of Anti-HIV Medicinal Products. CPMP/602/97, November 19, 1997.
13. Prentice RL. Surrogate markers in clinical trials: definition and operational criteria. Stat Med. 1989; 8:431-440.
14. Freedman LS, Graubard BL, Schatzkin A. Statistical validation of intermediate endpoints for chronic diseases. Stat Med. J992;ll:167-178.
15. Montaner J, DeMasi R, Dawson D, et al. Validation of HIV-1 RNA and CD4 count as surrogate markers in the CAESAR trial: preliminary results. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, June 28-30, 1997, St. Petersburg, FL. Abstract #61.
16. Tsiatis AA. Surrogate markers in AIDS clinical trials. Presented at the ENAR Meetings, March 18-20 1996, Richmond, VA.
17. Daniels MJ, Hughes MD. Meta-analysis for the evaluation of potential surrogate markers. Stat Med. 1997;16:1965-1982.